Upload
selina
View
64
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Antibiotics: Novel and Rediscovered. Stephen Swanson, MD, DTM&H Pediatric Infectious Diseases, Travel Medicine Department of Pediatrics Hennepin County Medical Center. β – lactams. Antibiotic Groups. PENICILLINS CEPHALOSPORINS Monobactams, Carbapenems Vancomycin (Glycopeptide) - PowerPoint PPT Presentation
Citation preview
Antibiotics:Novel and Rediscovered
Stephen Swanson, MD, DTM&HPediatric Infectious Diseases, Travel Medicine
Department of Pediatrics
Hennepin County Medical Center
Antibiotic Groups
• PENICILLINS
• CEPHALOSPORINS
• Monobactams, Carbapenems
• Vancomycin (Glycopeptide)
• Linezolid (Oxazolidinone)
• Aminoglycosides
• Macrolides
• Clindamycin
• Tetracyclines
• Sulfonamides plus trimethoprim
• Rifamycins
• Quinolones
• Metronidazole
β – lactams
Truth in Advertising
Objectives
• MRSA Epi Trends
• Old Antibiotics used for Gram-positive Infections
• Newer Antibiotics: on Horizon and Approved
S. aureus
Evolution of Drug Resistance in S. aureus
Methicillin
[1960s]
Methicillin-resistantS. aureus (MRSA)
S. aureus
Penicillin
[1950s]
Penicillin-resistant
CA-MRSA amongIV Drug Users)
[ 1981 ]
[ 1998 ]
“Community Acquired MRSA in Children With No Identified Predisposing Risk”
-JAMA
[ 1999 ]
4 Pediatric Deaths in
MN and ND
- MMWR
...
..
........
Minnesota Population Distribution and Sentinel Hospital Laboratories
CA-MRSA in MN: a shift from USA400 to USA300 lineage
CA-MRSA in MN: a shift from USA400 to USA300 lineage
USA300 MRSA (predominant lineage) is more susceptible to
clindamycin
Erythromycin 17 %
Clindamycin 95 %
Ciprofloxacin 72 %
Tetracycline 96 %
TMP/SMX 100 %
Gentamicin 100 %
Vancomycin 100 %
Linezolid 100 %
Rifampin 99 %
Mupirocin 97 %
Antibiotic % Susceptible
Source: MDH
CA-MRSA Antibiotic Susceptibilities in MN, 2006 (N=492)
CA-MRSA Antibiotic Susceptibilities in MN, 2006 (N=492)
Erythromycin 17 %
Clindamycin 95 %
Ciprofloxacin 72 %
Tetracycline 96 %
TMP/SMX 100 %
Gentamicin 100 %
Vancomycin 100 %
Linezolid 100 %
Rifampin 99 %
Mupirocin 97 %
Antibiotic % Susceptible
Source: MDH
Epidemiologic Trends of MRSA:USA300 and USA100
• USA300 strain more common among:
– Patients < 20 years
– ~92% susceptible to clindamycin
– Wound/abscess
• USA100
– Blood, lower respiratory tract
– Elderly (age > 65)
– 95% resistance to clindamycin
Activity of Ceftaroline and Epidemiologic Trends of Staphlyococcus aureus collected from 43 Medical Center in the United States in 2009; Richter et al., Antimicrob Agents Chemother. 2011
CA-MRSA Antibiotic Susceptibilities in MN, 2006 (N=492)
Erythromycin 17 %
Clindamycin 95 %
Ciprofloxacin 72 %
Tetracycline 96 %
TMP/SMX 100 %
Gentamicin 100 %
Vancomycin 100 %
Linezolid 100 %
Rifampin 99 %
Mupirocin 97 %
Antibiotic % Susceptible
Source: MDH
CA-MRSA Antibiotic Susceptibilities in MN, 2006 (N=492)
Erythromycin 17 %
Clindamycin 95 %
Ciprofloxacin 72 %
Tetracycline 96 %
TMP/SMX 100 %
Gentamicin 100 %
Vancomycin 100 %
Linezolid 100 %
Rifampin 99 %
Mupirocin 97 %
Antibiotic % Susceptible
Source: MDH
What about rifampin and gentamicin?
Clinical Practice Guidelines by IDSA for MRSA - 2011
• Addition of gentamicin or rifampin for bacteremia or native valve infective endocarditis not recommended in adults (A-II, A-1 evidence)
• Data in children insufficient to support routine use of combination therapy.
• Osteomyelitis – maybe helpful
• Pneumonia – not likely helpful
• Eradication – never rifampin monotherapy
BACTRIM:
Why Bactrim Might Fail with ca-MRSA infections…
Why Bactrim Might Fail with MRSA infections…
Why Bactrim Might Fail with MRSA infections…
Take-home: Avoid TMP-SMX monotherapy if significant
amount of tissue damage/necrosis
MRSA necrotizing pneumonia following influenza
Vancomycin Limitations: Newer Gram-positive Antibiotics Needed
• Burden of MRSA increasing
• USA300 entering hospital system
• Treatment failures and poor outcomes with Vancomycin
– Variable dosing/levels
– Limited penetration of bone, lung epithelial fluid, CSF
– Slow killing time, especially higher inocula
• MIC creep (> 2 μg/mL) requires higher dosing
Linezolid
• Oxazolidinone-class antibiotic– Inhibits protein synthesis– Excellent bioavailability– Excellent CSF penetration
• Covers GAS, S. pneumoniae, MSSA/MRSA, enterococcus, Listeria, oral anaerobes– Uses:
• Pneumonia• Complicated SSTI• Osteomyelitis• Meningitis*
– Failures: endocarditis (static)• Major side effect: reversible myelosuppression
– Follow weekly CBC if using > 2 weeks
Minocycline – the forgotten child
• Oral and IV• Can be used in MRSA SSTI• Data lacking for more invasive infections• Very active against MRSA and CONS embedded in
biofilms on catheters
Raad I., et al.Antimicrob. Agents Chemother, May 2007
Ceftaroline fosamil (Teflaro)
• 5th generation cephalosporin
• Low propensity for inducing resistance
• Excellent safety profile
• Gram-positive bacteria (CONS, MRSA, VISA, VRSA, resistant pneumococcus, resp gram negs)
– 4-fold greater activity against MRSA than Vanc
– 16-fold greater activity against MSSA than Ceftr
– Active against daptomycin- and linezolid-resistant staph
• Avoid in ESBLs, Pseudomonas, Acinetobacter
• FDA approved in 2010 for CAP and cSSTI (adults)
Ceftobiprole - another 5th gen ceph
• Active against MRSA
• Approved in Canada
• FDA approval pending further evaluation
The newer antibiotics… never to be approved for children?
Daptomycin
An old drug, that did not receive FDA approval until 2003
Rapid killing of almost all clinically relevant gram-positive bacteria
Effective all stages of bacterial growth
T. Greenhow, MD
Daptomycin
Clinical trials in complicated SSTIs showed it was equivalent to nafcillin / vancomycin Cure rate >96% Currently indicated for complicated SSTIs (adult)
Drug was found to be less effective than ceftriaxone in treating community-acquired pneumonia– Binds to surfactant which reduces its activity in the alveolar
spaces of the lung
Carpenter, CF and HF Chambers CID 2004Hancock, RE Lancet 2005
Daptomycin
Approved for right-sided endocarditis, S. aureus bacteremia (6mg/kg)
Prolonged half-life (once daily dosing) Monitor weekly CPK levels (dose-dependent,
reversible) Not FDA approved in 2 – 17 year olds, but literature
increasingly supportive Pregnancy B category
Carpenter, CF and HF Chambers CID 2004Hancock, RE Lancet 2005N Engl J Med 2006; 355:653-665Adura M, et. al. “Daptomycin therapy for invasive Gram-positive bacterial infections in children.” PIDJ 2007: 1128-1132
Daptomycin Pediatric Dosing
Dosing under study. Recommended starting doses: Complicated SSTI
9 mg/k IV QD (ages 2-6) 7 mg/kg IV QD (ages 7-11) 5 mg/kg IV QD (ages 12-17)
Osteomyelitis, Septic Arthritis, Bacteremia 6-10 mg/kg IV daily
Failures more likely in patients with prior vancomycin exposure or elevated vancomycin MICs (adult data)
Final notes
• Azithromycin resistance rates– >20% for S. pneumoniae– 5-10+% for GAS
• Clindamycin– S. pneumoniae (~88% susceptible)– Group A streptococcus (~10% inducible
resistance)– Group B streptococcus (~70% susceptible)
Thank you.